1Villadsen LS, Skov L, Baadsgaard O. Biological response modifiers and their potential use in the treatment of inflammatory skin diseases. Exp Dermatol, 2003, 12: 1-10.
2Willems M, Munte K, Vrolijk JM, et al. Hyperpigmentation during interferon -alpha therapy for chronic hepatitis C virus infection. Br J Dermatol, 2003, 149: 390-394.
3Dereure O, Raison-Peyron N, Larrey D, et al. Diffuse inflammatory lesions in patients treated with interferon alfa and ribavirin for hepatitis C: a series of 20 patients. Br J Dermatol, 2002, 147:1142-1146.
4Tursen U, Kaya TI, lkizoglu G. Interferon-alpha 2b induced facial erythema in a woman with chronic hepatitis C infection. J Eur Aead Dermatol Venereol, 2002, 16:285-286.
5Wendling J, Descamps V, Grossin M, et al.Sarcoidosis during combined interferon alfa and ribavirin therapy in 2 patients with chronic hepatitis C. Arch Dermatol, 2002,138: 546-547.
6Stafford-Fox V, Guindon KM. Cutaneous reactions associated with alpha interferon therapy. Clin J Oncol Nurs, 2000, 4: 164-168.
7Sanders S, Busam K, Tahan SR, et al.Granulomatous and suppurative dermatitis at interferon alfa injection sites: report of 2 cases. J Am Acad Dermatol, 2002, 46:611-616.
8Sanlpaio EP, Moreira AL, Sarno EN, et al.Prolonged treatment with recombinant interferon gamma induces erythema nodosum leprosum in lepromatous leprosy patients. J Exp Med, 1992, 175: 1729-1737.
9Mazzeo L, Ricciardi L, Fazio MC, et al. Severe urticaria due to recombinant interferon beta-la. Br J Derrnatol, 2003, 148: 172.
10van Rengen A, Goossens A. Local reactions after subcutaneous injections of beta-interferon. Contact Dermatitis, 1998.39: 209.
3Pinto JM, Marques MS, Correia TE. Lichen planus and leukocytoclastic vasculitis induced by interferon alpha-2b in a subject with HCV-related chronic active hepatitis[J]. J Eur Acad Dermatol Venereol, 2003, 17(2):193- 195.
4Sanchez-Perez J, De Castro M, Buezo GF, et al. Lichen planus and hepatitis C virus: prevalence and clinical presentation of patients with lichen planus and hepatitis C virus infection[J]. Br J Dermatol, 1996, 134(4):715-719.
5Kaya S, Arslan E, Baysal B, et al. Lichen planus induced by pegylated interferon alfa-2a therapy in a patient monitored for delta hepatitis[J]. Case Rep Infect Dis, 2015, 2015:389131.
6Tezak Z, Hoffman EP, Lutz JL, et al. Gene expression profiling in DQA1*0501+ children with untreated dermatomyositis: a novel model of pathogenesis[J]. J Immunol, 2002, 168(8):4154-4163.
7Uzel G, Pachman LM. Cytokines in juvenile dermatomyositis pathophysiology: potential and challenge[J]. Curr Opin Rheumatol, 2003, 15(6):691-697.
8Matikainen S, Sareneva T, Ronni T, et al. Interferon-alpha activates multiple STAT proteins and upregulates proliferation-associated IL-2Ralpha, c -myc, and pim-1 genes in human T cells[J]. Blood, 1999, 93(6):1980-1991.
9Marrack P, Kappler J, Mitchell T. Type I interferons keep activated T cells alive[J]. J Exp Med, 1999, 189(3):521-530.
10Suomela S,Cao L, Bowcock A, Saarialho-Kere U. Interferon alpha-inducible protein 27(IFI27)is upregulated in psoriatic skin and certain epithelial cancers[J]. J Invest Dermatol, 2004, 122(3):717-721.
